Core Viewpoint - Aimeike has received approval for its injectable type A botulinum toxin product, marking its first such product and the seventh in China, indicating a strategic expansion into the botulinum toxin market [1][2]. Group 1: Product Development and Market Position - Aimeike's foray into botulinum toxin began in 2021 with the acquisition of a 25.42% stake in Huons BioPharma for 856 million yuan [1]. - The newly approved product is positioned as a conventional offering in a market already populated by six established competitors, including Allergan's Botox and domestic brands like Hengli and LeTibao [2][4]. - The approval of Aimeike's botulinum toxin product is seen as a potential third growth driver for the company, although its market differentiation remains uncertain [2][5]. Group 2: Competitive Landscape - The competitive landscape for botulinum toxin products is characterized by established players with clear differentiation and market positioning, making it challenging for Aimeike to carve out a unique space [5][6]. - Aimeike's pricing strategy will significantly influence its market performance, as it may need to align closely with mainstream market prices to achieve sales targets [6][7]. - The existing products in the market have established brand loyalty and clinical advantages, particularly Allergan's Botox, which dominates the high-end market with multiple approved indications [6][7]. Group 3: Financial Performance and Market Trends - Aimeike's core products, including Hyaluronic Acid and PLLA-based fillers, have experienced slowing growth, reflecting increased competition in the aesthetic medicine sector [7][10]. - The revenue from Aimeike's Hyaluronic Acid products is projected to decline, with a significant drop of 23.79% expected in the first half of 2025 [13]. - The market for aesthetic injectables is becoming increasingly competitive, with over 40 brands of hyaluronic acid products approved in China, leading to price pressures and declining profit margins [18][19].

上海昊海生物科技股份有限公司 H 股同步公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 12 月 12 日，上海昊海生物科技股份有限公司（以下简称"公司"） 召开第六届董事会第六次会议和第六届董事会独立董事第二次专门会议，审议通 过了《关于购买股权暨与关联人共同投资的议案》，同意公司以自有资金人民币 38,351,487.36 元受让苗九昌、苗春云合计持有的江西瑞济生物工程技术股份有限 公司（以下简称"瑞济生物"）8,466,112 股股份，占瑞济生物总股本的 19.8000% （以下简称"本次交易"）。本次受让股权后将形成与关联人共同投资。本次交 易未涉及与关联人之间发生资金往来或权属转移。具体详见公司于 2025 年 12 月 13 日在上海证券交易所网站（www.sse.com.cn）披露的《上海昊海生物科技股份 有限公司关于购买股权暨与关联人共同投资的公告》（公告编号：2025-050）及 在香港联合交易所网站（www.hkexnews.hk）同步发布的相关 H 股公告。 2026 年 1 月 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 38,529,240 | RMB | | 1 RMB | | 38,529,240 | | 增加 / 減少 (-) | | | -2,019,500 | | | RMB | | -2,019,500 | | 本月底結存 | | | 36,509,740 | RMB | | ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-053 上海昊海生物科技股份有限公司 关于注销已回购 H 股股份暨控股股东、实际控制人及其 一致行动人权益变动被动触及 1%刻度的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 9 月 15 日至 2025 年 12 月 4 日期间，公司已实际回购 H 股股份 2,019,500 股，占公司总股本的 0.87%，使用资金总额 5,561.5776 万港元（不含交 易税费）。 根据公司 2024 年度股东周年大会、2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东大会决议，本次回购的 H 股股份将全部注销并相应减少 公司注册资本。 二、本次回购注销的办理情况 重要内容提示： 总股本变动情况：2025 年 12 月 29 日，上海昊海生物科技股份有限公司 （以下简称"公司"）回购的 2,019,500 股 H 股股份完成注销，公司的总股本由 232,581,095 股变更为 230,561,595 股。 权益变动 ...

第 1 頁 共 8 頁 v 1.3.0 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | | 是 | | | | | 證券代號 (如上市) | | 06826 | 說明 | H 股 | | | | | | | | | | ...

上海昊海生物科技有限公司于2025年12月22日购回17,000股H股，价格介乎25.54至25.60港元，总代价 434,916港元，股份拟注销。此次购回依据2025年6月10日通过的授权进行，累计已购回2,516,600股，占 当时已发行股份的6.4294%。 截至2025年12月26日收盘，昊海生科（688366）报收于44.63元，较上周的44.83元下跌0.45%。本周， 昊海生科12月22日盘中最高价报45.15元。12月24日盘中最低价报44.04元，股价触及近一年最低点。昊 海生科当前最新总市值103.8亿元，在医疗器械板块市值排名33/127，在两市A股市值排名1854/5178。 本周关注点 公司公告汇总 上海昊海生物科技股份有限公司公告，控股股东、实际控制人之一蒋伟先生因非本公司事项，收到中国 证监会《行政处罚决定书》（[2025]151号）。因其存在内幕交易及建议他人买卖证券行为，证监会决 定没收其违法所得4,709,741.41元，并处以14,629,224.23元罚款。该事项与公司无关，蒋伟不参与公司日 常经营，公司生产经营正常开展。 以上内容为证券之星据公开信息整理，由AI算法生 ...

Core Viewpoint - The medical aesthetics industry is entering a "cooling period" by 2025, with increasing competition leading to performance declines for upstream companies, making it challenging for leading manufacturers to maintain high growth rates. Price wars are becoming inevitable as the number of competitors rises, and conflicts over product pricing and agency rights are escalating among companies [1][2][4]. Industry Overview - The medical aesthetics market is approaching saturation, with many listed companies experiencing significant declines in performance. For instance, Huaxi Biological reported a revenue drop of 18.36% and a net profit decline of 30.29% for the first three quarters of the year. Similarly, Aimeike experienced a revenue decrease of 21.49% and a net profit drop of 31.05% [2][3]. - Despite the current challenges, industry experts remain optimistic about the future growth of the medical aesthetics market, projecting a double-digit growth rate driven by consumer preferences and increasing demand for aesthetic procedures [3][4]. Competitive Landscape - The approval of various hyaluronic acid and collagen products has intensified competition, leading to a "price war" among manufacturers. The market for "童颜针" (AestheFill) has seen a significant increase in competition, with multiple products now available, creating a scenario referred to as "九子夺嫡" (Nine Princes Competing for the Throne) [4][5][6]. - The pricing strategies of downstream institutions are causing conflicts with upstream manufacturers, as some institutions adopt low-price strategies that disrupt traditional pricing systems [4][5]. Mergers and Acquisitions - The industry is witnessing a wave of mergers and acquisitions as companies seek to acquire technology, brands, or channel resources. Notable transactions include Aimeike's acquisition of a majority stake in Korean REGEN and Bausch Health's acquisition of Wuhan Zhibo Zhenmei Technology [6][7]. - The trend of consolidation is expected to continue, with both upstream and downstream companies engaging in strategic acquisitions to enhance their market positions and operational efficiencies [7].

Core Viewpoint - The insider trading case involving Jiang Wei, the actual controller of Haohai Biological Technology (688366.SH), has concluded with a total penalty of 19.34 million yuan, highlighting governance concerns within the company as it faces growth challenges and declining performance [1][2][5]. Group 1: Insider Trading Case - Jiang Wei was penalized by the China Securities Regulatory Commission (CSRC) for insider trading and advising others to trade securities, resulting in a total fine and confiscation of 19.34 million yuan [1][5]. - The investigation lasted seven months, reflecting the current regulatory environment's strict stance against insider trading, with half of the CSRC's administrative penalties this year related to such cases [5][7]. - Jiang Wei has never held a position in the listed company and does not participate in daily operations, yet he and his wife control 45.82% of the company's shares [1][5]. Group 2: Company Performance and Governance - Haohai Biological Technology is experiencing a growth bottleneck, with 2024 revenue at 2.698 billion yuan, a mere 1.64% increase, marking the first single-digit growth since 2021 [2][10]. - The company has seen a decline in both revenue and net profit in the first three quarters of 2025, with revenue down 8.47% and net profit down over 10% [2]. - The governance structure is questioned as Jiang Wei's influence persists despite his absence from operational roles, raising concerns about the "behind-the-scenes boss" model [8][12]. Group 3: Business Challenges - The company faces significant challenges in its ophthalmology segment, with revenue from artificial lenses down 14.06% and viscoelastic agents down 19.53% due to centralized procurement policies [10]. - Although the aesthetic medicine segment remains a growth driver, the growth rate of hyaluronic acid products has sharply decreased from 95.45% in 2023 to 23.23% [10]. - Haohai is attempting to diversify by acquiring a 19.8% stake in Ruijie Biological for 38.35 million yuan, despite the target company being in a loss-making state [10].

Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. announced that its actual controller, Mr. Jiang Wei, received regulatory penalties for personal actions in the securities market, which has drawn market attention [1][4]. Group 1: Regulatory Actions - Mr. Jiang Wei was penalized by the China Securities Regulatory Commission for insider trading and advising others to trade securities, with the investigation process taking several months from the initial notice to the final decision [1][4]. - The company clarified that the penalties are directed at Mr. Jiang personally and are unrelated to the operations of Haohai Biological, emphasizing that he does not participate in daily management [1][4]. Group 2: Company Operations and Governance - Despite the personal nature of the incident, it has prompted scrutiny of the company's governance structure and future development, as Haohai Biological is a well-known entity in the biomedical materials sector and the first pharmaceutical company listed on both the Hong Kong Stock Exchange and the STAR Market [2][5]. - The long-term value of the company is contingent upon the development potential of its core business and market competitiveness, particularly in the fields of medical aesthetics and ophthalmology, which are recognized for their growth prospects but also face challenges such as industry competition and market demand fluctuations [2][5][6]. - The management's focus should be on maintaining stable operations while driving technological innovation and strengthening market position to gain long-term trust from the capital market, which is more critical than addressing a single incident [2][6].

Report Summary 1. Report Industry Investment Rating No relevant information provided. 2. Core Viewpoints - On December 23, the liquidity remained loose; the entry of allocation funds boosted the bond market to strengthen with fluctuations; the convertible bond market adjusted, with most convertible bond issues declining; yields of U.S. Treasuries across maturities generally rose, while yields of 10 - year government bonds in major European economies generally fell [1] 3. Summary by Directory 3.1 Bond Market News 3.1.1 Domestic News - President Xi Jinping emphasized that central enterprises should serve the overall situation, optimize the layout of the state - owned economy, strengthen R & D of key core technologies, deepen reforms, and balance development and security [3] - Premier Li Qiang pointed out that during the "15th Five - Year Plan" period, central enterprises should play a key role in infrastructure construction, ensure the autonomy and controllability of the industrial chain, support technological self - reliance, serve national strategies, and deepen state - owned enterprise reforms [4] - The National Housing and Urban - Rural Development Work Conference stated that during the "15th Five - Year Plan" period, the real estate market has great potential. It is necessary to establish a new development model, implement city - specific policies, and promote the healthy development of the real estate market [6] 3.1.2 International News - The U.S. GDP in Q3 grew at an annualized quarterly rate of 4.3%, exceeding expectations. Consumer spending was strong, while investment performance was divided, with non - residential investment slowing and residential investment dragging down the economy [7] - In October, U.S. durable goods orders decreased by 2.2% month - on - month, worse than expected. However, the year - on - year growth rate remained positive, and core orders showed resilience [8] 3.1.3 Commodities - On December 23, international crude oil futures prices continued to rise, and international natural gas prices rose by over 10%. Gold futures also saw an increase [9] 3.2 Liquidity 3.2.1 Open Market Operations - On December 23, the central bank conducted 593 billion yuan of 7 - day reverse repurchase operations at a fixed interest rate of 1.40%. With 1353 billion yuan of reverse repurchases maturing, the net capital withdrawal was 760 billion yuan [11] 3.2.2 Funding Rates - On December 23, the liquidity remained loose. DR001 decreased by 0.14bp to 1.269%, and DR007 decreased by 2.32bp to 1.411%. Other funding rates also showed various changes [12][13] 3.3 Bond Market Dynamics 3.3.1 Interest - Bearing Bonds - On December 23, the bond market strengthened with fluctuations due to the obvious entry of allocation funds. Yields of 10 - year Treasury and China Development Bank bonds both decreased by 0.85bp. Yields of bonds across other maturities also generally declined [14][15] - There were no Treasury or China Development Bank bond issuances on that day [16] 3.3.2 Credit Bonds - On December 23, the trading prices of two industrial bonds deviated by over 10%, with "21 Vanke 06" falling by over 10% and "23 Vanke MTN001" rising by over 23% [17] - Multiple companies announced important events, including cancellations of proposals, legal disputes, disciplinary actions, and the completion of restructuring plans [20] 3.3.3 Convertible Bonds - On December 23, the three major A - share indices rose. The convertible bond market adjusted, with major indices falling. The trading volume increased. Most convertible bond issues declined, with some issues rising or falling significantly [19] - Jin 05 Convertible Bond will start online subscription on December 25. Some convertible bonds announced early redemptions or were about to trigger early redemption conditions [25] 3.3.4 Overseas Bond Markets - On December 23, yields of U.S. Treasuries across maturities generally rose. The yield spread between 2 - year and 10 - year U.S. Treasuries narrowed by 3bp, and the 10 - year inflation - protected Treasury (TIPS) break - even inflation rate rose by 1bp [22][23][24] - Yields of 10 - year government bonds in major European economies generally fell [26] - The prices of some Chinese - funded U.S. dollar bonds changed. The top 10 gainers and losers had different price movements [28]